Glioblastoma organoids for selection of personalized therapies
2022
Luxembourg Institute of Health, Dudelange, Luxembourg(1)
Mannheim Center for Translational Neurosciences, Mannheim, Germany(2)
Mannheim Center for Translational Neurosciences, Mannheim, Germany(2)
This study describes the establishment of a patient-derived glioblastoma organoid (PD-GBO) based functional profiling platform and the results of its application to four patient tumors. It was shown that the PD-GBO model system preserves key features of individual patient glioblastomas. As proof of concept, a panel of 41 FDA-approved drugs was tested and used to identify potential treatment options for three out of four patients within a turnaround from tumor resection to discovery of treatment options of 13, 14, and 15 days, respectively. These results demonstrate that PD-GBOs can be used for effective personalized treatment discovery in a clinically relevant time period. Furthermore, these results warrant the use of PD-GBO platforms for the preclinical identification of new drugs against defined morphological glioblastoma features.
Patient-derived tumor organoids for guidance of personalized drug therapies in recurrent glioblastoma
Yong-Jun Kwon(1), Miriam Ratliff(2)
Added on: 10-14-2022
[1] https://www.mdpi.com/1422-0067/23/12/6572
